08:00 , Nov 13, 2006 |  BC Week In Review  |  Clinical News

Ii-Key/H5 influenza vaccine: Phase I start

This month, GNBT will start a Phase I trial in 160 healthy volunteers. Generex Biotechnology Corp. (GNBT), Toronto, Ontario   Product: Ii-Key/H5 influenza vaccine   Business: Infectious   Molecular target: NA   Description: Peptide vaccine containing Ii-Key modified...